X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

The Supreme Court’s recent FTC v. Actavis, Inc. decision on reverse payment settlement agreements arising in Hatch-Waxman litigation sets the stage for federal district courts to navigate a still-uncertain landscape concerning these types of settlement agreements. This shifting landscape represents significant risk for innovator drug manufacturers unless and until the lower courts clarify the analytical framework.

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.